SCHEMBL7569009

SCHEMBL7569009

COc1ccc(CNC(=O)c2cc(C#N)ccc2NC2CCCN(C=O)C2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 1/20 0.43
PDE7A Q13946 1/20 0.42
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
RAB9A P51151 1/20 0.40
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40
APEX1 P27695 1/20 0.40
FAP Q12884 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564997 0.96 PDE7A (0.44) ALDH1A1SMN1; SMN2KDM4EPDE7AACHE
SCHEMBL7679020 0.96 PDE7A (0.44) ALDH1A1SMN1; SMN2KDM4EPDE7AACHE
SCHEMBL7565006 0.96 PDE7A (0.44) ALDH1A1SMN1; SMN2KDM4EPDE7AACHE
SCHEMBL7565906 0.91 ACHE (0.43) ALDH1A1SMN1; SMN2KDM4EPDE7AACHE
SCHEMBL7563845 0.87 RAB9A (0.54) ALDH1A1SMN1; SMN2KDM4ERAB9AGAA
SCHEMBL7565400 0.86 ACHE (0.45) ALDH1A1SMN1; SMN2KDM4EACHEBACE1
SCHEMBL7598322 0.86 ACHE (0.45) ALDH1A1SMN1; SMN2KDM4EACHEBACE1
SCHEMBL7565390 0.86 ACHE (0.45) ALDH1A1SMN1; SMN2KDM4EACHEBACE1
SCHEMBL7566293 0.85 ACHE (0.41) ALDH1A1SMN1; SMN2KDM4EACHEBACE1
SCHEMBL7566674 0.85 ACHE (0.45) ALDH1A1SMN1; SMN2KDM4EACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A ALDH1A1 253/4885SMN1; SMN2 3616/4885KDM4E 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.